Vertex Pharmaceuticals (VRTX) Revenue & Revenue Breakdown
Vertex Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$9.84B
Latest Revenue (Q)
$2.65B
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Vertex Pharmaceuticals Revenue by Period
Vertex Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $9.84B | 10.17% |
| 2022-12-31 | $8.93B | 17.91% |
| 2021-12-31 | $7.57B | 22.06% |
| 2020-12-31 | $6.21B | 49.07% |
| 2019-12-31 | $4.16B | 36.59% |
| 2018-12-31 | $3.05B | 22.46% |
| 2017-12-31 | $2.49B | 46.20% |
| 2016-12-31 | $1.70B | 64.89% |
| 2015-12-31 | $1.03B | 77.86% |
| 2014-12-31 | $580.41M | -52.11% |
| 2013-12-31 | $1.21B | -20.63% |
| 2012-12-31 | $1.53B | 8.25% |
| 2011-12-31 | $1.41B | 883.91% |
| 2010-12-31 | $143.37M | 40.49% |
| 2009-12-31 | $102.05M | -41.85% |
| 2008-12-31 | $175.50M | -11.81% |
| 2007-12-31 | $199.01M | -8.02% |
| 2006-12-31 | $216.36M | 34.47% |
| 2005-12-31 | $160.89M | 56.63% |
| 2004-12-31 | $102.72M | 48.56% |
| 2003-12-31 | $69.14M | -57.08% |
| 2002-12-31 | $161.09M | -3.82% |
| 2001-12-31 | $167.49M | 114.38% |
| 2000-12-31 | $78.13M | 26.83% |
| 1999-12-31 | $61.60M | 38.74% |
| 1998-12-31 | $44.40M | 1.37% |
| 1997-12-31 | $43.80M | 229.32% |
| 1996-12-31 | $13.30M | -39.82% |
| 1995-12-31 | $22.10M | 12.76% |
| 1994-12-31 | $19.60M | -29.75% |
| 1993-12-31 | $27.90M | - |
Vertex Pharmaceuticals generated $9.84B in revenue during NA 2023, up 10.17% compared to the previous quarter, and up 322.84% compared to the same period a year ago.
Vertex Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $2.65B | -1.55% |
| 2024-03-31 | $2.69B | 6.73% |
| 2023-12-31 | $2.52B | 1.38% |
| 2023-09-30 | $2.48B | -0.39% |
| 2023-06-30 | $2.49B | 4.99% |
| 2023-03-31 | $2.37B | 3.13% |
| 2022-12-31 | $2.30B | -1.35% |
| 2022-09-30 | $2.33B | 6.29% |
| 2022-06-30 | $2.20B | 4.71% |
| 2022-03-31 | $2.10B | 1.20% |
| 2021-12-31 | $2.07B | 4.46% |
| 2021-09-30 | $1.98B | 10.64% |
| 2021-06-30 | $1.79B | 4.01% |
| 2021-03-31 | $1.72B | 5.93% |
| 2020-12-31 | $1.63B | 5.82% |
| 2020-09-30 | $1.54B | 0.90% |
| 2020-06-30 | $1.52B | 0.62% |
| 2020-03-31 | $1.52B | 7.21% |
| 2019-12-31 | $1.41B | 48.79% |
| 2019-09-30 | $949.83M | 0.91% |
| 2019-06-30 | $941.29M | 9.65% |
| 2019-03-31 | $858.43M | -1.34% |
| 2018-12-31 | $870.11M | 10.91% |
| 2018-09-30 | $784.53M | 4.30% |
| 2018-06-30 | $752.16M | 17.38% |
| 2018-03-31 | $640.80M | -1.66% |
| 2017-12-31 | $651.63M | 12.71% |
| 2017-09-30 | $578.16M | 6.25% |
| 2017-06-30 | $544.13M | -23.87% |
| 2017-03-31 | $714.72M | 55.81% |
| 2016-12-31 | $458.71M | 10.86% |
| 2016-09-30 | $413.78M | -4.13% |
| 2016-06-30 | $431.61M | 8.42% |
| 2016-03-31 | $398.08M | -4.75% |
| 2015-12-31 | $417.94M | 34.90% |
| 2015-09-30 | $309.82M | 86.55% |
| 2015-06-30 | $166.08M | 19.90% |
| 2015-03-31 | $138.51M | -4.18% |
| 2014-12-31 | $144.56M | -19.24% |
| 2014-09-30 | $178.99M | 29.31% |
| 2014-06-30 | $138.42M | 16.86% |
| 2014-03-31 | $118.45M | -66.27% |
| 2013-12-31 | $351.16M | 58.39% |
| 2013-09-30 | $221.70M | -28.66% |
| 2013-06-30 | $310.75M | -5.37% |
| 2013-03-31 | $328.37M | -1.68% |
| 2012-12-31 | $333.99M | -0.60% |
| 2012-09-30 | $336.01M | -19.67% |
| 2012-06-30 | $418.31M | -4.66% |
| 2012-03-31 | $438.74M | -22.12% |
| 2011-12-31 | $563.34M | -14.54% |
| 2011-09-30 | $659.20M | 476.10% |
| 2011-06-30 | $114.42M | 55.34% |
| 2011-03-31 | $73.66M | 12.42% |
| 2010-12-31 | $65.52M | 175.37% |
| 2010-09-30 | $23.80M | -24.75% |
| 2010-06-30 | $31.62M | 40.99% |
| 2010-03-31 | $22.43M | -33.82% |
| 2009-12-31 | $33.89M | 35.79% |
| 2009-09-30 | $24.96M | 30.91% |
| 2009-06-30 | $19.06M | -20.50% |
| 2009-03-31 | $23.98M | -26.92% |
| 2008-12-31 | $32.81M | 3.80% |
| 2008-09-30 | $31.61M | -54.46% |
| 2008-06-30 | $69.41M | 66.55% |
| 2008-03-31 | $41.67M | - |
Vertex Pharmaceuticals generated $2.65B in revenue during Q2 2024, up -1.55% compared to the previous quarter, and up 111.40% compared to the same period a year ago.
Vertex Pharmaceuticals Revenue Breakdown
Vertex Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $9.87B | $4.16B | - | - | - |
| ORKAMBI | $326.00M | $510.70M | $771.60M | $907.51M | $1.33B |
| KALYDECO | $475.50M | $553.20M | $684.20M | $802.87M | $991.06M |
| TRIKAFTA/KAFTRIO | $8.94B | $7.69B | $5.70B | $3.86B | - |
| SYMDEKO/SYMKEVI | $123.00M | $180.00M | $420.40M | $628.58M | $1.42B |
| Collaborative and Royalty | - | - | $1.00M | $2.90M | $2.10M |
| TRIKAFTA | - | - | - | - | $420.11M |
Vertex Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (50.00%), TRIKAFTA/KAFTRIO (45.32%), KALYDECO (2.41%), ORKAMBI (1.65%), and SYMDEKO/SYMKEVI (0.62%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRIKAFTA/KAFTRIO | $2.45B | $2.48B | $2.33B | $2.27B | $2.24B | $2.10B | $2.02B | $2.01B | $1.89B | $1.76B | $1.69B | $1.56B | $1.26B | $1.19B | $1.09B | $960.31M | - | - | - | - |
| ORKAMBI | - | - | $44.20M | $63.00M | $96.30M | $122.50M | $110.80M | $146.20M | $121.60M | $132.10M | $147.38M | $184.56M | $220.97M | $218.70M | $215.47M | $225.92M | $231.98M | $234.14M | $425.73M | $296.71M |
| KALYDECO | - | - | $112.40M | $112.80M | $125.30M | $125.00M | $136.10M | $139.40M | $138.70M | $139.00M | $152.15M | $162.42M | $183.29M | $186.34M | $193.37M | $193.87M | $203.06M | $212.58M | $235.58M | $249.40M |
| SYMDEKO/SYMKEVI | - | - | $27.80M | $33.40M | $31.20M | $30.60M | $34.30M | $38.20M | $42.70M | $64.80M | $80.43M | $81.42M | $133.50M | $125.05M | $127.51M | $156.18M | $171.73M | $173.16M | - | - |
| Collaborative and Royalty | - | - | - | - | - | - | - | - | - | - | - | $900.00K | - | - | - | - | - | - | - | - |
| TRIKAFTA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $917.72M | $895.23M | - | - |
| Product | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.41B | - |
| SYMDEKO | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $403.71M |
Vertex Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: TRIKAFTA/KAFTRIO (100.00%).
Vertex Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Outside the United States | $3.83B | $3.23B | $2.29B | $1.38B | $1.10B |
| Other Countries Outside of the United States and Europe | $719.80M | $525.90M | $313.20M | $249.94M | $214.50M |
| Europe | $3.11B | $2.71B | $1.97B | $1.13B | $885.76M |
| UNITED STATES | $6.04B | $5.70B | $5.29B | $4.83B | $3.06B |
Vertex Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (44.10%), Outside the United States (27.95%), Europe (22.70%), and Other Countries Outside of the United States and Europe (5.25%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $1.61B | $1.52B | $1.57B | $1.55B | $1.51B | $1.40B | $1.46B | $1.42B | $1.37B | $1.38B | $1.26B | $1.25B | $1.21B | $1.22B | $1.21B | $1.19B | $1.01B | $710.32M | $700.62M | $641.10M |
| Europe | $806.80M | $967.40M | $735.30M | $766.50M | $800.00M | $807.20M | $730.50M | $655.50M | $632.30M | $518.83M | $458.91M | $404.97M | $360.02M | $251.37M | $257.68M | $257.39M | $352.95M | $184.84M | $180.20M | $167.75M |
| Non-US | $1.03B | $1.17B | $929.30M | $985.40M | $971.00M | $878.70M | $781.10M | $729.30M | $601.27M | $536.45M | $469.87M | $313.71M | $314.17M | $327.52M | $239.50M | $240.68M | $217.33M | - | - | - |
| Other, Non U.S. | $224.50M | $203.30M | $162.80M | $185.40M | $163.80M | $148.20M | $125.60M | $97.00M | $82.45M | $77.54M | $64.90M | $62.34M | $56.49M | $70.13M | $54.66M | $60.48M | $49.58M | - | - | - |
Vertex Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (43.90%), Non-US (28.05%), Europe (21.94%), and Other, Non U.S. (6.11%).
Vertex Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | $13.12B | $3.55B |
| VRTX | Vertex Pharmaceuticals | $9.84B | $2.65B |
| MRNA | Moderna | $6.85B | $241.00M |
| BNTX | BioNTech SE | $3.82B | $187.60M |
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $659.83M |
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| CRSP | CRISPR Therapeutics | $370.00M | $517.00K |
| DNA | Ginkgo Bioworks | $251.46M | $56.21M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| NTLA | Intellia Therapeutics | $36.27M | $6.96M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| VERV | Verve Therapeutics | $11.76M | $5.70M |
| EDIT | Editas Medicine | - | - |
| VKTX | Viking Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
VRTX Revenue FAQ
What is Vertex Pharmaceuticals’s yearly revenue?
Vertex Pharmaceuticals's yearly revenue for 2023 was $9.84B, representing an increase of 10.17% compared to 2022. The company's yearly revenue for 2022 was $8.93B, representing an increase of 17.91% compared to 2021. VRTX's yearly revenue for 2021 was $7.57B, representing an increase of 22.06% compared to 2020.
What is Vertex Pharmaceuticals’s quarterly revenue?
Vertex Pharmaceuticals's quarterly revenue for Q2 2024 was $2.65B, a -1.55% decrease from the previous quarter (Q1 2024), and a 6.11% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $2.69B, a 6.73% increase from the previous quarter (Q4 2023), and a 13.15% increase year-over-year (Q1 2023). VRTX's quarterly revenue for Q4 2023 was $2.52B, a 1.38% increase from the previous quarter (Q3 2023), and a 9.34% increase year-over-year (Q4 2022).
What is Vertex Pharmaceuticals’s revenue growth rate?
Vertex Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 29.90%, and for the last 5 years (2019-2023) was 136.35%.
What are Vertex Pharmaceuticals’s revenue streams?
Vertex Pharmaceuticals's revenue streams in c 23 are Product, ORKAMBI, KALYDECO, TRIKAFTA/KAFTRIO, and SYMDEKO/SYMKEVI. Product generated $9.87B in revenue, accounting 50.00% of the company's total revenue, up 137.20% year-over-year. ORKAMBI generated $326M in revenue, accounting 1.65% of the company's total revenue, down -36.17% year-over-year. KALYDECO generated $475.5M in revenue, accounting 2.41% of the company's total revenue, down -14.05% year-over-year. TRIKAFTA/KAFTRIO generated $8.94B in revenue, accounting 45.32% of the company's total revenue, up 16.36% year-over-year. SYMDEKO/SYMKEVI generated $123M in revenue, accounting 0.62% of the company's total revenue, down -31.67% year-over-year.
What is Vertex Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Vertex Pharmaceuticals was Product. This segment made a revenue of $9.87B, representing 50.00% of the company's total revenue.